anikatherapeutics.com - ANIK Short-Term Debt to Capital

Anika Therapeutics develops innovative joint restoration methods, utilizing unique hyaluronic acid developments to minimize surgical intervention. This chart reflects that the asset value on GURU.Markets is 0.01, which correlates with the active hiring of tissue regeneration experts and significant investments in scientific research. Meanwhile, Anika Therapeutics strictly controls production waste utilization and biomaterial safety.

Anika Therapeutics maintains stable component supply chains for its medical devices through the diversification of its raw material base. By analyzing the ratio of short-term loans to equity, an investor assesses the alignment of obligations with maturities of up to one year against equity. This metric determines liquidity risk and the impact of current loans on the weighted average cost of capital (WACC). Optimizing this balance confirms the business's financial stability and the absence of cash gap threats.